Indoco Remedies’ solid dosages manufacturing facility at Baddi receives UK MHRA approval
Our Bureau, Mumbai
Wednesday, May 8, 2019, 13:30 Hrs [IST]
Indoco Remedies Limited, a Rs. 1,000 plus pharma major, has received approval from the UK MHRA (Medicines and Healthcare Products Regulatory Agency) for its new solid dosages manufacturing facility in Baddi, Himachal Pradesh (Baddi III unit). The inspection was held from 16th to 18th October, 2018.
Commenting on the approval, Aditi Panandikar, managing director, Indoco Remedies Limited, said, "This is the first regulatory inspection for the plant, which was acquired in 2016. The outcome of this inspection is positive and is a testimony that Indoco maintains global quality standards and follows strict GMP guidelines. The facility will cater mainly to the European markets”.
The facility is spread over an area of 18,000 sqm, with manufacturing capacity of 4.3 billion tablets and 50 million capsules per annum.
Indoco Remedies Ltd., a fully integrated, research-oriented pharma company with presence in 55 countries. Indoco, a USD 161 million company, employs over 5,500 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D centre and a CRO facility.
|